Basilea Pharmaceutica AG: Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing

Related Keywords

China ,Japan ,Basilea ,Basel Stadt ,Switzerland ,United States ,Canada ,Brazil ,Swiss ,Nils Schr ,Basel Allschwil ,Marc Engelhardt ,Asahi Kasei Pharma ,Laurenz Kellenberger ,David Veitch ,Us Department Of Health ,Human Services ,Head Of Corporate Communications Investor Relations ,Biomedical Advanced Research ,Drug Administration ,Merck Co ,Administration For Strategic Preparedness ,Development Authority ,Swiss Exchange ,Basilea Pharmaceutica Ltd ,Basilea Pharmaceutica International Ltd ,New Drug Application ,Pharmaceutica Ltd ,Chief Executive Officer ,Asia Pacific ,Chief Medical Officer ,Chief Scientific Officer ,Corporate Communications ,Pharmaceutica International Ltd ,Strategic Preparedness ,Compared With Vancomycin Plus Aztreonam ,Acute Bacterial Skin ,Skin Structure Infections ,Double Blind Trial ,Clinical Infectious Diseases ,Pharmaceutica ,Reports ,Reliminary ,022 ,Revenues ,Exceeding ,Guidance ,Rovides ,Portfolio ,Update ,